

(43) International Publication Date
12 November 2009 (12.11.2009)(10) International Publication Number
WO 2009/136350 A1

(51) International Patent Classification:

C07D 513/10 (2006.01) **A61P 25/28** (2006.01)
A61K 31/4436 (2006.01)

(21) International Application Number:

PCT/IB2009/051815

(22) International Filing Date:

4 May 2009 (04.05.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/050,423 5 May 2008 (05.05.2008) US

(71) Applicant (for all designated States except US): **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **BRODNEY, Michael, Aaron** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US). **HELAL, Christopher, John** [US/US]; PfizerGlobal Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US). **O'NEILL, Brian, Thomas** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US).(74) Agents: **RICHARDSON, Peter C.** et al.; Pfizer Inc. 235 East 42nd Street, New York, New York 10017 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,

[Continued on next page]

(54) Title: NOVEL CLASS OF SPIRO PIPERIDINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES



(57) Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.



WO 2009/136350 A1



TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:**Declarations under Rule 4.17:**

- *as to the identity of the inventor (Rule 4.17(i))*
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

- *with international search report (Art. 21(3))*